Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Cardiff Oncology's Enterprise Value is $127.70 Mil.
Cardiff Oncology's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 was $-52.10 Mil. Therefore, Cardiff Oncology's EV-to-EBIT ratio for today is -2.45.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Cardiff Oncology's Enterprise Value is $127.70 Mil.
Cardiff Oncology's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 was $-51.68 Mil. Therefore, Cardiff Oncology's EV-to-EBITDA ratio for today is -2.47.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Cardiff Oncology's Enterprise Value is $127.70 Mil.
Cardiff Oncology's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 was $0.59 Mil. Therefore, Cardiff Oncology's EV-to-Revenue ratio for today is 217.18.
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Cardiff Oncology's Enterprise Value is $127.70 Mil.
Cardiff Oncology's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2025 was $-42.75 Mil. Therefore, Cardiff Oncology's EV-to-FCF ratio for today is -2.99.
Cardiff Oncology Enterprise Value Historical Data
The historical data trend for Cardiff Oncology's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Cardiff Oncology's Enterprise Value
For the Biotechnology subindustry, Cardiff Oncology's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cardiff Oncology's Enterprise Value Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cardiff Oncology's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Cardiff Oncology's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Cardiff Oncology's Enterprise Value for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cardiff Oncology (NAS:CRDF) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Cardiff Oncology's current Enterprise Value is $127.70 Mil.
Cardiff Oncology's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-52.10 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Cardiff Oncology's current Enterprise Value is $127.70 Mil.
Cardiff Oncology's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-51.68 Mil.
Cardiff Oncology's current Enterprise Value is $127.70 Mil.
Cardiff Oncology's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.59 Mil.
Cardiff Oncology's current Enterprise Value is $127.70 Mil.
Cardiff Oncology's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-42.75 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cardiff Oncology Enterprise Value Related Terms
Thank you for viewing the detailed overview of Cardiff Oncology's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CRDF has been successfully added to your 